MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.830
-1.030
-26.68%
After Hours: 2.820 -0.01 -0.35% 17:55 05/27 EDT
OPEN
3.250
PREV CLOSE
3.860
HIGH
3.290
LOW
2.600
VOLUME
369.04K
TURNOVER
0
52 WEEK HIGH
41.00
52 WEEK LOW
2.160
MARKET CAP
29.21M
P/E (TTM)
-0.2541
1D
5D
1M
3M
1Y
5Y
41 Stocks Moving In Friday's Mid-Day Session
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
Benzinga · 1d ago
AVDL, SIGA, PSHG and IOVA among mid-day movers
 Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (A...
Seekingalpha · 1d ago
BRIEF-Tempest Reports Positive Tpst-1120 Clinical Data From Phase 1 Trial In Patients With Advanced Solid Tumors At 2022 Asco Annual Meeting
reuters.com · 1d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 2d ago
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting
RECIST responses observed in IO-refractory patients and in IO-resistant indications 30% ORR in patients treated at the two highest TPST-1120 doses in combination with nivolumab (3/10); 20% ORR in all evaluable combination patients (3/15)53% DCR in monother...
GlobeNewswire · 2d ago
BRIEF-Tempest Therapeutics Files Prospectus Related To Proposed Resale Of Up To 6,355,932 Shares
reuters.com · 05/16 22:17
Tempest Therapeutics GAAP EPS of -$1.18 misses by $0.06
Tempest Therapeutics press release (NASDAQ:TPST): Q1 GAAP EPS of -$1.18 misses by $0.06. Cash and cash equivalents of $45.8M.
Seekingalpha · 05/13 12:35
--HC Wainwright Adjusts Tempest Therapeutics Price Target to $35 From $51, Maintains Buy Rating
MT Newswires · 05/13 11:45
More
No Data
Learn about the latest financial forecast of TPST. Analyze the recent business situations of Tempest Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TPST stock price target is 22.50 with a high estimate of 35.00 and a low estimate of 10.00.
High35.00
Average22.50
Low10.00
Current 2.830
EPS
Actual
Estimate
-6.10-4.58-3.05-1.53
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 65
Institutional Holdings: 2.38M
% Owned: 23.04%
Shares Outstanding: 10.32M
TypeInstitutionsShares
Increased
4
4.03K
New
2
10.23K
Decreased
3
53.03K
Sold Out
6
209.99K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Director
Mike Raab
President/Director
Tom Dubensky
Chief Executive Officer/Director
Stephen Brady
Chief Financial Officer/Vice President - Finance
Nicholas Maestas
Other
Thomas Hoover
Other
Samuel Whiting
Director
Christine Pellizzari
Director
Ronit Simantov
Director
Tom Woiwode
Independent Director
Geoffrey Nichol
No Data
No Data
About TPST
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Webull offers kinds of Tempest Therapeutics Inc stock information, including NASDAQ:TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.